C&R Research
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
C&R Research manages clinical trials on behalf of pharmaceutical companies and biotech ventures, handling everything from study design and protocol development through statistical analysis and regulatory reporting, so drug developers can outsource the research process entirely.
Listed on KOSDAQ, Korea's tech and small-cap board, it serves domestic pharmaceutical firms and biotech startups as its primary clients. Its business is knowledge-intensive and requires no physical facilities or raw materials, with revenue recognised progressively over the life of each contracted project.
Summary is AI-generated and may contain errors · figures from DART filings
The company operates a subsidiary, Trial Informatics, to which it has transferred certain clinical-trial IT platform assets, running two distinct business lines, clinical trial services and clinical IT solutions, in parallel.
C&R Research in five facts
What does C&R Research do?
C&R Research manages clinical trials on behalf of pharmaceutical companies and biotech ventures, handling everything from study design and protocol development through statistical analysis and regulatory reporting, so drug developers can outsource the research process entirely.
Where is C&R Research listed and in which sector?
C&R Research (Korean name: 씨엔알리서치) trades under KRX code 359090 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is C&R Research?
Its market capitalisation was US$20M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were C&R Research's latest annual revenue and operating profit?
For fiscal year 2025, C&R Research reported revenue of US$49M, operating profit of US$1M and net income of US$770.7K, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 8.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Trading suspension (share consolidation/split registration)M&A · Jun 2
- Supply contract signed
C&R Research disclosed a supply contract with Daewoong Pharmaceutical, worth US$7.59M, about 17.71% of its recent annual revenue, running through Mar 2029.
Supply contract · Mar 30 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
C&R Research reported consolidated results for FY2025: revenue of US$45.1M (+8.9% year on year), operating profit of US$960K (−61.8% year on year) and net income of US$708K (−69.6% year on year).
Earnings · Feb 24 - Cash/in-kind dividend decision
C&R Research declared a cash dividend of US$0.01 per share.
Dividend · Feb 24 - [Amended] Supply contract signed
C&R Research updated a previously disclosed supply contract with a company, now worth US$4.32M, about 14.49% of its recent annual revenue, running through Feb 2026.
Supply contract · Feb 20 - [Amended] Supply contract signedSupply contract · Feb 9
- Decision to acquire shares/equity in another companyM&A · Jan 8